Apart from cell proliferation and apoptosis effects, two potent FTO inhibitors, CS1 and CS2, reduce leukemia stem cell self-renewal and enhance T cell cytotoxicity by reprogramming immune responses, highlighting FTO’s role in cancer stem cell self-renewal and immune evasion, as well as its potential as a cancer therapy target [99]. The gene discussed is FTO; the disease is cancer.